199 related articles for article (PubMed ID: 27993967)
1. An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies.
Beaver JA; Tzou A; Blumenthal GM; McKee AE; Kim G; Pazdur R; Philip R
Clin Cancer Res; 2017 Mar; 23(6):1368-1372. PubMed ID: 27993967
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers to improve the benefit/risk balance for approved therapeutics: a US FDA perspective on personalized medicine.
Sapsford KE; Tezak Z; Kondratovich M; Pacanowski MA; Zineh I; Mansfield E
Ther Deliv; 2010 Nov; 1(5):631-41. PubMed ID: 22833953
[TBL] [Abstract][Full Text] [Related]
3. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
4. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
Roscoe DM; Hu YF; Philip R
Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
[TBL] [Abstract][Full Text] [Related]
5. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
Philip R; Carrington L; Chan M
Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
[TBL] [Abstract][Full Text] [Related]
6. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
Senderowicz AM; Pfaff O
Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
[TBL] [Abstract][Full Text] [Related]
7. The FDA Oncology Center of Excellence and precision medicine.
Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
[TBL] [Abstract][Full Text] [Related]
8. Companion diagnostic testing for targeted cancer therapies: an overview.
Fan YS
Genet Test Mol Biomarkers; 2013 Jul; 17(7):515-23. PubMed ID: 23574530
[TBL] [Abstract][Full Text] [Related]
9. Challenges ahead for companion diagnostics.
Schmidt C
J Natl Cancer Inst; 2012 Jan; 104(1):14-5. PubMed ID: 22173588
[No Abstract] [Full Text] [Related]
10. International differences in companion diagnostic approvals: how are we able to manage the differences?
Shimazawa R; Ikeda M
Expert Rev Mol Diagn; 2015 Feb; 15(2):157-9. PubMed ID: 25308218
[TBL] [Abstract][Full Text] [Related]
11. Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives.
Jørgensen JT
Trends Cancer; 2016 Dec; 2(12):706-712. PubMed ID: 28741518
[TBL] [Abstract][Full Text] [Related]
12. Translating Immuno-oncology Biomarkers to Diagnostic Tests: A Regulatory Perspective.
Li Y; Veeraraghavan J; Philip R
Methods Mol Biol; 2020; 2055():701-716. PubMed ID: 31502175
[TBL] [Abstract][Full Text] [Related]
13. Regulatory landscapes for biomarkers and diagnostic tests: Qualification, approval, and role in clinical practice.
Mattes WB; Goodsaid F
Exp Biol Med (Maywood); 2018 Feb; 243(3):256-261. PubMed ID: 29110507
[TBL] [Abstract][Full Text] [Related]
14. The evolving potential of companion diagnostics.
Khoury JD
Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers as drug development tools: discovery, validation, qualification and use.
Kraus VB
Nat Rev Rheumatol; 2018 Jun; 14(6):354-362. PubMed ID: 29760435
[TBL] [Abstract][Full Text] [Related]
16. Approval gap of pharmacogenomic biomarkers and in vitro companion diagnostics between the United States and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2014 Apr; 39(2):210-4. PubMed ID: 24405254
[TBL] [Abstract][Full Text] [Related]
17. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.
Fridlyand J; Simon RM; Walrath JC; Roach N; Buller R; Schenkein DP; Flaherty KT; Allen JD; Sigal EV; Scher HI
Nat Rev Drug Discov; 2013 Oct; 12(10):743-55. PubMed ID: 24008432
[TBL] [Abstract][Full Text] [Related]
18. Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch.
Scheerens H; Malong A; Bassett K; Boyd Z; Gupta V; Harris J; Mesick C; Simnett S; Stevens H; Gilbert H; Risser P; Kalamegham R; Jordan J; Engel J; Chen S; Essioux L; Williams JA
Clin Transl Sci; 2017 Mar; 10(2):84-92. PubMed ID: 28121072
[TBL] [Abstract][Full Text] [Related]
19. Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.
Dobbin KK; Cesano A; Alvarez J; Hawtin R; Janetzki S; Kirsch I; Masucci GV; Robbins PB; Selvan SR; Streicher HZ; Zhang J; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():77. PubMed ID: 27891226
[TBL] [Abstract][Full Text] [Related]
20. Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization.
Amur S; LaVange L; Zineh I; Buckman-Garner S; Woodcock J
Clin Pharmacol Ther; 2015 Jul; 98(1):34-46. PubMed ID: 25868461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
